von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study

Sanaz Sedaghat; Paul S. de Vries; Johan Boender; Michelle A.H. Sonneveld; Ewout J. Hoorn; Albert Hofman; Moniek P.M. de Maat; Oscar H. Franco; M. Arfan Ikram; Frank W.G. Leebeek; Abbas Dehghan

doi:10.1053/j.ajkd.2016.05.032

von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study

Sanaz Sedaghat, Paul S. de Vries, Johan Boender, Michelle A.H. Sonneveld, Ewout J. Hoorn, Albert Hofman, Moniek P.M. de Maat, Oscar H. Franco, M. Arfan Ikram, Frank W.G. Leebeek, Abbas Dehghan

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background Altered levels of von Willebrand factor (vWF) and ADAMTS13 can promote thrombosis and disturb blood flow in kidney microcirculations. We investigated the association of serum vWF:ADAMTS13 ratio in relation to decline in kidney function. Study Design Prospective cohort study. Setting & Participants 2,479 individuals (mean age, 65.1 ± 5.9 [SD] years; 43% men) from the population-based Rotterdam Study. Predictors vWF, ADAMTS13, and vWF:ADAMTS13 ratio. Outcomes & Measurements Annual decline in estimated glomerular filtration rate (eGFR), halving of eGFR, and new-onset eGFR < 60 mL/min/1.73 m² were assessed. Results During a median follow-up of 11 (range, 7.81-13.57) years, 500 cases of new-onset eGFR < 60 mL/min/1.73 m² occurred. The population had a mean eGFR decline of 0.96 ± 0.92 mL/min/1.73 m² per year. Higher vWF:ADAMTS13 ratio was associated with steeper annual decline in eGFR (difference, −0.06 [95% CI, −0.09 to −0.02] mL/min/1.73 m² per year) and higher risk for new-onset eGFR < 60 mL/min/1.73 m² (OR, 1.13; 95% CI, 1.01-1.27). Likewise, higher vWF:ADAMTS13 ratio was associated with higher risk for halving of eGFR (OR, 1.40; 95% CI, 1.02-1.93). After adjustment for cardiovascular risk factors and blood group, effect estimates remained the same. Limitations No data available for albuminuria. Participants were classified based on a single measurement of vWF and ADAMTS13. Conclusions In this population-based study, we showed that higher vWF:ADAMTS13 ratio is associated with decline in kidney function, suggesting a role of elevated prothrombotic factors in the development and progression of kidney disease.

Original language	English (US)
Pages (from-to)	726-732
Number of pages	7
Journal	American Journal of Kidney Diseases
Volume	68
Issue number	5
DOIs	https://doi.org/10.1053/j.ajkd.2016.05.032
State	Published - Nov 1 2016
Externally published	Yes

Bibliographical note

Funding Information:
Support: The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission; and the Municipality of Rotterdam. The measurement of ADAMTS13 was financially supported by Baxalta Innovations GmbH , now part of Shire, Vienna, Austria through an unrestricted grant. Dr Dehghan is supported by Netherlands Organization for Scientific Research (NWO) grant (veni, 916.12.154) and the Erasmus University Rotterdam Fellowship. Dr Franco works in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd) , Metagenics Inc , and AXA . Nestlé Nutrition (Nestec Ltd), Metagenics Inc, and AXA had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript.

Publisher Copyright:
© 2016 National Kidney Foundation, Inc.

Keywords

ADAMTS13 activity
disease progression
eGFR trajectory
estimated glomerular filtration rate (eGFR)
kidney disease
prothrombotic factors
von Willebrand factor (vWF)
von Willebrand factor protease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1053/j.ajkd.2016.05.032

Find It

Find It at U of M Libraries

Cite this

Sedaghat, S., de Vries, P. S., Boender, J., Sonneveld, M. A. H., Hoorn, E. J., Hofman, A., de Maat, M. P. M., Franco, O. H., Ikram, M. A., Leebeek, F. W. G., & Dehghan, A. (2016). von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study. American Journal of Kidney Diseases, 68(5), 726-732. https://doi.org/10.1053/j.ajkd.2016.05.032

@article{00ea5afb7bf34e3b9ccd2acd3517c55c,

title = "von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study",

abstract = "Background Altered levels of von Willebrand factor (vWF) and ADAMTS13 can promote thrombosis and disturb blood flow in kidney microcirculations. We investigated the association of serum vWF:ADAMTS13 ratio in relation to decline in kidney function. Study Design Prospective cohort study. Setting & Participants 2,479 individuals (mean age, 65.1 ± 5.9 [SD] years; 43% men) from the population-based Rotterdam Study. Predictors vWF, ADAMTS13, and vWF:ADAMTS13 ratio. Outcomes & Measurements Annual decline in estimated glomerular filtration rate (eGFR), halving of eGFR, and new-onset eGFR < 60 mL/min/1.73 m2 were assessed. Results During a median follow-up of 11 (range, 7.81-13.57) years, 500 cases of new-onset eGFR < 60 mL/min/1.73 m2 occurred. The population had a mean eGFR decline of 0.96 ± 0.92 mL/min/1.73 m2 per year. Higher vWF:ADAMTS13 ratio was associated with steeper annual decline in eGFR (difference, −0.06 [95% CI, −0.09 to −0.02] mL/min/1.73 m2 per year) and higher risk for new-onset eGFR < 60 mL/min/1.73 m2 (OR, 1.13; 95% CI, 1.01-1.27). Likewise, higher vWF:ADAMTS13 ratio was associated with higher risk for halving of eGFR (OR, 1.40; 95% CI, 1.02-1.93). After adjustment for cardiovascular risk factors and blood group, effect estimates remained the same. Limitations No data available for albuminuria. Participants were classified based on a single measurement of vWF and ADAMTS13. Conclusions In this population-based study, we showed that higher vWF:ADAMTS13 ratio is associated with decline in kidney function, suggesting a role of elevated prothrombotic factors in the development and progression of kidney disease.",

keywords = "ADAMTS13 activity, disease progression, eGFR trajectory, estimated glomerular filtration rate (eGFR), kidney disease, prothrombotic factors, von Willebrand factor (vWF), von Willebrand factor protease",

author = "Sanaz Sedaghat and {de Vries}, {Paul S.} and Johan Boender and Sonneveld, {Michelle A.H.} and Hoorn, {Ewout J.} and Albert Hofman and {de Maat}, {Moniek P.M.} and Franco, {Oscar H.} and Ikram, {M. Arfan} and Leebeek, {Frank W.G.} and Abbas Dehghan",

note = "Funding Information: Support: The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission; and the Municipality of Rotterdam. The measurement of ADAMTS13 was financially supported by Baxalta Innovations GmbH , now part of Shire, Vienna, Austria through an unrestricted grant. Dr Dehghan is supported by Netherlands Organization for Scientific Research (NWO) grant (veni, 916.12.154) and the Erasmus University Rotterdam Fellowship. Dr Franco works in ErasmusAGE, a center for aging research across the life course funded by Nestl{\'e} Nutrition (Nestec Ltd) , Metagenics Inc , and AXA . Nestl{\'e} Nutrition (Nestec Ltd), Metagenics Inc, and AXA had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. Publisher Copyright: {\textcopyright} 2016 National Kidney Foundation, Inc.",

year = "2016",

month = nov,

day = "1",

doi = "10.1053/j.ajkd.2016.05.032",

language = "English (US)",

volume = "68",

pages = "726--732",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function

T2 - A Population-Based Cohort Study

AU - Sedaghat, Sanaz

AU - de Vries, Paul S.

AU - Boender, Johan

AU - Sonneveld, Michelle A.H.

AU - Hoorn, Ewout J.

AU - Hofman, Albert

AU - de Maat, Moniek P.M.

AU - Franco, Oscar H.

AU - Ikram, M. Arfan

AU - Leebeek, Frank W.G.

AU - Dehghan, Abbas

N1 - Funding Information: Support: The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission; and the Municipality of Rotterdam. The measurement of ADAMTS13 was financially supported by Baxalta Innovations GmbH , now part of Shire, Vienna, Austria through an unrestricted grant. Dr Dehghan is supported by Netherlands Organization for Scientific Research (NWO) grant (veni, 916.12.154) and the Erasmus University Rotterdam Fellowship. Dr Franco works in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd) , Metagenics Inc , and AXA . Nestlé Nutrition (Nestec Ltd), Metagenics Inc, and AXA had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. Publisher Copyright: © 2016 National Kidney Foundation, Inc.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background Altered levels of von Willebrand factor (vWF) and ADAMTS13 can promote thrombosis and disturb blood flow in kidney microcirculations. We investigated the association of serum vWF:ADAMTS13 ratio in relation to decline in kidney function. Study Design Prospective cohort study. Setting & Participants 2,479 individuals (mean age, 65.1 ± 5.9 [SD] years; 43% men) from the population-based Rotterdam Study. Predictors vWF, ADAMTS13, and vWF:ADAMTS13 ratio. Outcomes & Measurements Annual decline in estimated glomerular filtration rate (eGFR), halving of eGFR, and new-onset eGFR < 60 mL/min/1.73 m2 were assessed. Results During a median follow-up of 11 (range, 7.81-13.57) years, 500 cases of new-onset eGFR < 60 mL/min/1.73 m2 occurred. The population had a mean eGFR decline of 0.96 ± 0.92 mL/min/1.73 m2 per year. Higher vWF:ADAMTS13 ratio was associated with steeper annual decline in eGFR (difference, −0.06 [95% CI, −0.09 to −0.02] mL/min/1.73 m2 per year) and higher risk for new-onset eGFR < 60 mL/min/1.73 m2 (OR, 1.13; 95% CI, 1.01-1.27). Likewise, higher vWF:ADAMTS13 ratio was associated with higher risk for halving of eGFR (OR, 1.40; 95% CI, 1.02-1.93). After adjustment for cardiovascular risk factors and blood group, effect estimates remained the same. Limitations No data available for albuminuria. Participants were classified based on a single measurement of vWF and ADAMTS13. Conclusions In this population-based study, we showed that higher vWF:ADAMTS13 ratio is associated with decline in kidney function, suggesting a role of elevated prothrombotic factors in the development and progression of kidney disease.

AB - Background Altered levels of von Willebrand factor (vWF) and ADAMTS13 can promote thrombosis and disturb blood flow in kidney microcirculations. We investigated the association of serum vWF:ADAMTS13 ratio in relation to decline in kidney function. Study Design Prospective cohort study. Setting & Participants 2,479 individuals (mean age, 65.1 ± 5.9 [SD] years; 43% men) from the population-based Rotterdam Study. Predictors vWF, ADAMTS13, and vWF:ADAMTS13 ratio. Outcomes & Measurements Annual decline in estimated glomerular filtration rate (eGFR), halving of eGFR, and new-onset eGFR < 60 mL/min/1.73 m2 were assessed. Results During a median follow-up of 11 (range, 7.81-13.57) years, 500 cases of new-onset eGFR < 60 mL/min/1.73 m2 occurred. The population had a mean eGFR decline of 0.96 ± 0.92 mL/min/1.73 m2 per year. Higher vWF:ADAMTS13 ratio was associated with steeper annual decline in eGFR (difference, −0.06 [95% CI, −0.09 to −0.02] mL/min/1.73 m2 per year) and higher risk for new-onset eGFR < 60 mL/min/1.73 m2 (OR, 1.13; 95% CI, 1.01-1.27). Likewise, higher vWF:ADAMTS13 ratio was associated with higher risk for halving of eGFR (OR, 1.40; 95% CI, 1.02-1.93). After adjustment for cardiovascular risk factors and blood group, effect estimates remained the same. Limitations No data available for albuminuria. Participants were classified based on a single measurement of vWF and ADAMTS13. Conclusions In this population-based study, we showed that higher vWF:ADAMTS13 ratio is associated with decline in kidney function, suggesting a role of elevated prothrombotic factors in the development and progression of kidney disease.

KW - ADAMTS13 activity

KW - disease progression

KW - eGFR trajectory

KW - estimated glomerular filtration rate (eGFR)

KW - kidney disease

KW - prothrombotic factors

KW - von Willebrand factor (vWF)

KW - von Willebrand factor protease

UR - http://www.scopus.com/inward/record.url?scp=84994805545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994805545&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2016.05.032

DO - 10.1053/j.ajkd.2016.05.032

M3 - Article

C2 - 27497525

AN - SCOPUS:84994805545

SN - 0272-6386

VL - 68

SP - 726

EP - 732

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 5

ER -

von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this